Internal Medicine, Medical Oncology · Palm Beach Gardens, FL
NPI
1598785966
Since 2006
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
3401 Pga Blvd Ste 200
Palm Beach Gardens, FL, 33410
Phone (561) 366-4100
Groups this clinician bills Medicare through
Medicare paid, 2024
$3.5M
274,340 services
Medicare patients, 2024
879
Average age 76
Drug cost, 2024
$5.1M
1,534 prescriptions
Company payments, 2025
$6,211
From 44 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Sumithra Vattigunta was code Q5110 (injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram), 30,360 times for 13 patients. In total Sumithra Vattigunta billed 274,340 services in 167 codes, and Medicare paid $3.5M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-06-12.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| Q5110 Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram | Office | 30,360 | 13 | $0.22 | $6,538 |
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 16,320 | 17 | $0.27 | $4,472 |
| J9271 Injection, pembrolizumab, 1 mg | Office | 14,600 | 17 | $44.52 | $650K |
| Q5101 Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | Office | 11,460 | 11 | $0.17 | $1,986 |
| J0185 Injection, aprepitant, 1 mg | Office | 9,750 | 19 | $1.33 | $13K |
| Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 6,280 | 73 | $0.09 | $595 |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 5,800 | 49 | $15.85 | $92K |
| J1434 Injection, fosaprepitant (focinvez), 1 mg | Office | 5,400 | 14 | $2.22 | $12K |
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 4,240 | 24 | $6.40 | $27K |
| J0897 Injection, denosumab, 1 mg | Office | 3,660 | 45 | $20.57 | $75K |
| 85025 Blood Count | Office | 2,584 | 676 | $7.60 | $20K |
| 36415 Venipuncture Blood Collection | Office | 2,187 | 662 | $8.62 | $19K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 2,148 | 44 | $0.09 | $192 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 1,680 | 36 | $0.73 | $1,234 |
| 99214 Office E&M - Established | Office | 1,296 | 454 | $99.58 | $129K |
By year: 2022 $3.0M for 191,564 services; 2023 $2.7M for 196,744 services; 2024 $3.5M for 274,340 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 2,584 | 676 | $7.60 | $20K |
| 36415 Venipuncture Blood Collection | 2,187 | 662 | $8.62 | $19K |
| 85610 Clinical Chemistry | 45 | 11 | $4.20 | $189 |
| 81003 Clinical Chemistry | 37 | 22 | $2.20 | $81.4 |
| 85045 Blood Count | 28 | 26 | $3.91 | $109 |
| 85046 Blood Count | 13 | 13 | $5.08 | $65.98 |
Medicare prescription drug claims, 2024
In 2024, the drug Sumithra Vattigunta prescribed most often to Medicare patients was Anastrozole, with 129 prescriptions and refills. In total Sumithra Vattigunta wrote 1,534 Medicare prescriptions that cost $5.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 129 | 357 | 42 | $2,393 |
| Eliquis Apixaban | 90 | 115 | 20 | $65K |
| Letrozole Generic | 65 | 187 | 21 | $1,560 |
| Gabapentin Generic | 55 | 64 | 19 | $546 |
| Xtandi Enzalutamide | 50 | 50 | Under 11 | $713K |
| Ibrance Palbociclib | 49 | 49 | Under 11 | $785K |
| Dexamethasone Generic | 45 | 63 | 15 | $754 |
| Prednisone Generic | 40 | 55 | 15 | $303 |
| Hydroxyurea Generic | 39 | 77 | 12 | $1,124 |
| Xarelto Rivaroxaban | 35 | 63 | Under 11 | $35K |
| Acyclovir Generic | 35 | 62 | 14 | $449 |
| Revlimid Lenalidomide | 35 | 35 | Under 11 | $606K |
| Levothyroxine Sodium Generic | 34 | 78 | 11 | $258 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 34 | 34 | Under 11 | $762 |
| Tamoxifen Citrate Generic | 31 | 90 | Under 11 | $1,217 |
Brand drugs: 480 claims; generic drugs: 1,054 claims; opioid claims: 64.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Sumithra Vattigunta $6,211 ($6,211 in general payments such as food, travel and fees) from 44 companies. The largest payer was Novartis Pharmaceuticals Corporation with $1,365.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 54 | $1,365 |
| Janssen Biotech, Inc. JNJ | 33 | $497 |
| Pfizer Inc. PFE | 40 | $417 |
| AstraZeneca Pharmaceuticals LP AZN | 15 | $386 |
| Daiichi Sankyo Inc. 4568.T | 17 | $369 |
| Celgene Corporation BMY | 19 | $269 |
| Abbvie Inc. ABBV | 13 | $268 |
| Incyte Corporation INCY | 9 | $207 |
| Merck Sharp & Dohme LLC MRK | 8 | $198 |
| Genentech USA, Inc. ROG.SW | 9 | $191 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.